ERBB2 and non-small cell lung carcinoma: Cohort 4 of the ZENITH20 trial enrolled 80 naïve patients with HER2 MUT NSCLC treated with 16 mg once daily or 8 mg twice daily (alternative schedule to try to reduce the toxicity).